The Hemodynamic Paradox of Valve-in-Valve TAVR: Redefining ‘Optimal’ Gradients and Patient-Prosthesis Mismatch

Highlights

• The STS/ACC TVT Registry analysis of 13,054 patients reveals a non-linear relationship between post-procedural mean gradients (MG) and 5-year mortality in Valve-in-Valve (ViV) TAVR.
• Contrary to traditional expectations, a low discharge mean gradient (<10 mm Hg) is associated with a 15% increase in 5-year mortality risk (HR 1.15) compared to higher gradients.
• Low discharge gradients in ViV-TAVR are often a marker of lower left ventricular ejection fraction (LVEF) rather than superior valve performance, suggesting a ‘low-flow’ state.
• Severe patient-prosthesis mismatch (PPM) and high residual gradients (≥20 mm Hg) were not significantly associated with worse 5-year outcomes, prompting a re-evaluation of aggressive valve optimization strategies.

Background

Transcatheter aortic valve-in-valve replacement (ViV-TAVR) has emerged as the preferred alternative to redo surgical aortic valve replacement (SAVR) for patients with degenerated bioprosthetic valves. While ViV-TAVR offers lower perioperative morbidity, it is frequently limited by high residual transvalvular gradients and patient-prosthesis mismatch (PPM) due to the fixed, often restrictive diameter of the initial surgical frame. Historically, clinical success in ViV-TAVR was defined by achieving the lowest possible mean gradient (MG). However, recent evidence from native TAVR populations suggested that very low gradients might actually be markers of poor ventricular function or ‘low-flow’ states rather than exceptional valve hemodynamics. Understanding whether this paradox persists in the ViV-TAVR population is critical for determining the necessity of intraprocedural adjuncts like bioprosthetic valve fracture (BVF) or larger valve sizing.

Key Content

The STS/ACC TVT Registry Analysis: Methodology and Population

The study by Abbas et al. (2026) utilized the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry to evaluate 13,054 patients who underwent ViV-TAVR with balloon-expandable valves between July 2015 and December 2023. This represents the largest cohort to date assessing mid-term outcomes (up to 5 years) in the ViV context. The investigators employed adjusted Cox models with regression splines to map the relationship between discharge echocardiographic MG and survival. Patients were stratified by gradient thresholds (<10 mm Hg vs. ≥10 mm Hg and <20 mm Hg vs. ≥20 mm Hg) and by the presence of PPM (none/moderate vs. severe).

The Low-Gradient Paradox and Mortality

The most striking finding of the analysis was the non-linear, almost U-shaped relationship between hemodynamics and survival. Spline curves indicated that the risk of mortality was highest at the lowest ends of the gradient spectrum. Specifically, patients discharged with an MG <10 mm Hg faced a significantly higher 5-year mortality rate compared to those with MG ≥10 mm Hg (Hazard Ratio [HR], 1.15; 95% CI, 1.02-1.29; P=0.024). This counter-intuitive finding suggests that a ‘perfect’ hemodynamic result on paper—very low resistance—may be a clinical red flag.

LVEF and the ‘Low-Flow’ Phenotype

Further investigation into the physiological profile of these patients revealed that the <10 mm Hg group had significantly lower mean ejection fractions (50.4±13.9% vs. 53.2±12.8%; P<0.0001). In these cases, the low gradient likely does not reflect a lack of obstruction, but rather the inability of a failing left ventricle to generate sufficient flow across the valve. This ‘pseudo-normalization’ of the gradient masks the underlying severity of cardiac dysfunction, which ultimately drives the poorer 5-year survival outcomes. This mirrors the ‘low-flow, low-gradient’ aortic stenosis phenotype seen in native valves, where the prognosis is dictated more by myocardial reserve than by the valve orifice area alone.

Re-evaluating Patient-Prosthesis Mismatch (PPM) in ViV-TAVR

Another major departure from surgical dogma was the observation regarding PPM. In surgical literature, severe PPM is strongly linked to premature bioprosthesis failure and increased mortality. However, in this balloon-expandable ViV-TAVR cohort, severe PPM was not associated with worse 5-year outcomes compared to none or moderate PPM. Similarly, a residual MG ≥20 mm Hg—the traditional threshold for ‘failed’ hemodynamics—did not correlate with increased mortality compared to MG <20 mm Hg. These results suggest that the left ventricle may tolerate the slightly higher resistance of a ViV configuration better than it tolerates the underlying comorbidities or the myocardial damage associated with the low-flow state.

The Role of Systemic Calcification and Vascular Risk

While the Abbas study focused on valve hemodynamics, broader evidence from the DANCAVAS trials (PMID: 41766556) highlights that the TAVR population remains at high risk for systemic events. Severe aortic and iliac calcifications serve as potent predictors of aortic dissection, aneurysm rupture, and major adverse limb events (MALEs), with subdistribution hazard rates reaching up to 13.52 for iliac calcification. This underscores the importance of viewing the ViV-TAVR patient as a high-risk vascular patient where valve gradients are only one piece of the survival puzzle.

Expert Commentary

The findings from the STS/ACC TVT Registry demand a shift in how interventional cardiologists interpret post-ViV-TAVR echocardiograms. For years, the ‘quest for the single digit gradient’ has driven clinicians toward more complex procedures, such as bioprosthetic valve fracture or aggressive over-expansion. However, if a gradient of 15 mm Hg is associated with better survival than a gradient of 8 mm Hg (because the former indicates a robust LV), we must ask if these optimization maneuvers are always necessary.

Clinicians should prioritize a holistic ‘flow-centric’ assessment rather than a ‘gradient-centric’ one. If a patient has a low gradient but also a low LVEF or a low stroke volume index, the prognosis is likely guarded, and ‘optimizing’ the valve further may provide no survival benefit. Conversely, the lack of association between severe PPM/high gradients and mortality in the mid-term suggests that for many elderly ViV-TAVR candidates, the current balloon-expandable platforms provide ‘good enough’ hemodynamics to outlive their other competitive risks. We must also consider the potential for favorable reverse remodeling after TAVR; as seen in VT ablation studies (PMID: 41766535), reducing cardiac stress can lead to volume reduction and improved function, but only if the myocardium has the biological capacity to recover.

Conclusion

ViV-TAVR with balloon-expandable valves is a clinically effective therapy, but its hemodynamic success cannot be measured by mean gradients in isolation. A discharge MG <10 mm Hg is a marker of increased 5-year mortality, primarily driven by underlying LV dysfunction and low-flow states. Furthermore, the mid-term survival of ViV patients does not appear to be significantly hampered by severe PPM or moderate residual gradients (20–30 mm Hg). Future research should focus on whether aggressive valve optimization (e.g., BVF) improves outcomes specifically in the subset of patients with *normal* flow and high gradients, rather than applying these techniques broadly. For now, the integration of LVEF and flow data with echocardiographic gradients is mandatory before determining the clinical success of a ViV-TAVR procedure.

References

• Abbas AE, et al. Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves. Circ Cardiovasc Interv. 2026. PMID: 41657207.
• Rungby MS, et al. Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials. Circulation. 2026. PMID: 41766556.
• Ghaleh B, et al. Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation. Circulation. 2026. PMID: 41766535.